SAR442970 for Ulcerative Colitis
(COLOR UC Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Ulcerative Colitis. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Ulcerative Colitis. The total study duration is up to 168 weeks, with a treatment period of up to 158 weeks including an open-label (OL) long-term extension (LTE) period of up to 104 weeks for eligible participants
Are You a Good Fit for This Trial?
Adults with moderate to severe Ulcerative Colitis (UC) for at least 3 months, confirmed by endoscopy. Participants must have an inadequate response or intolerance to standard UC treatments like corticosteroids and not been exposed to advanced therapies, or have had an inadequate response to at least one advanced therapy.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive SAR442970 or placebo for up to 158 weeks, including dose-ranging and assessment of efficacy and safety
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension
Participants may opt into continuation of treatment with SAR442970 for up to 104 weeks
What Are the Treatments Tested in This Trial?
Interventions
- SAR442970
Find a Clinic Near You
Who Is Running the Clinical Trial?
Sanofi
Lead Sponsor
Paul Hudson
Sanofi
Chief Executive Officer since 2019
Degree in Economics from Manchester Metropolitan University
Christopher Corsico
Sanofi
Chief Medical Officer
MD from Cornell University, MPH in Chronic Disease Epidemiology from Yale University